Advertisement
Screener

RECURSION PHARMACEUTICALS, INC. (RXRX) Long-Lived Assets

2.8 / 5 stars · 68/120 Roast Me

RECURSION PHARMACEUTICALS, INC. Long-Lived Assets

RECURSION PHARMACEUTICALS, INC. (RXRX) had Long-Lived Assets of $103.93 million as of 2025-12-31, per its 10-K filed 2026-02-25.

Financial Statements › Notes › Segment Reporting

us-gaap:NoncurrentAssets · last filed 2026-02-25

  • 2025-12-31: Long-Lived Assets $103.93M.
  • 2024-12-31: Long-Lived Assets $141.06M.
  • 2023-12-31: Long-Lived Assets $86.51M.
Period endLong-Lived Assets
2025-12-31$103.93M
10-K · filed 2026-02-25
2024-12-31$141.06M
10-K · filed 2026-02-25
2023-12-31$86.51M
10-K · filed 2026-02-25

Similar stocks

Stock NameCountryMarket CapPE Ratio
Kodiak Sciences Inc. (KOD)United States$2.090B-10.12
ADMA BIOLOGICS, INC. (ADMA)United States$2.131B11.16
Vericel Corp (VCEL)United States$2.011B93.97
BIOCRYST PHARMACEUTICALS INC (BCRX)United States$2.175B-6.63
Vir Biotechnology, Inc. (VIR)United States$1.814B-6.85
Greenland Mines Ltd (GRML)United States$2.362B
NOVAVAX INC (NVAX)United States$1.748B-6.26
Hemab Therapeutics Holdings, Inc. (COAG)United States$1.672B
Immunocore Holdings plc (IMCR)$1.613B-90.43
Beam Therapeutics Inc. (BEAM)United States$2.549B-41.51